Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
ConclusionsA more pronounced pathologic tumor response to NAT in BRPC is correlated with node negative disease, but was not associated with a statistically significant survival benefit in this study.
Source: Hepatobiliary and Pancreatic Diseases International - Category: Gastroenterology Source Type: research
More News: Adenocarcinoma | Borderline Tumor | Cancer | Cancer & Oncology | Gastroenterology | Liver | Liver Disease | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Pathology | Statistics | Study | Urology & Nephrology